183 related articles for article (PubMed ID: 36906459)
1. mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations.
Auvin S; Baulac S
Rev Neurol (Paris); 2023 Apr; 179(4):337-344. PubMed ID: 36906459
[TBL] [Abstract][Full Text] [Related]
2. Precision Therapy for Epilepsy Related to Brain Malformations.
D'Gama AM; Poduri A
Neurotherapeutics; 2021 Jul; 18(3):1548-1563. PubMed ID: 34608615
[TBL] [Abstract][Full Text] [Related]
3. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
Jeong A; Wong M
J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
6. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
7. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
8. Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma.
Sarnat HB; Flores-Sarnat L
Brain Dev; 2015 Jun; 37(6):553-62. PubMed ID: 25451314
[TBL] [Abstract][Full Text] [Related]
9. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
10. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
[TBL] [Abstract][Full Text] [Related]
11. mTOR signaling in epilepsy: insights from malformations of cortical development.
Crino PB
Cold Spring Harb Perspect Med; 2015 Apr; 5(4):. PubMed ID: 25833943
[TBL] [Abstract][Full Text] [Related]
12. mTOR pathway activation in focal cortical dysplasia.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M
Ann Diagn Pathol; 2020 Jun; 46():151523. PubMed ID: 32325422
[TBL] [Abstract][Full Text] [Related]
13. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
Aronica E; Specchio N; Luinenburg MJ; Curatolo P
Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
[TBL] [Abstract][Full Text] [Related]
14. Epilepsy in the mTORopathies: opportunities for precision medicine.
Moloney PB; Cavalleri GL; Delanty N
Brain Commun; 2021; 3(4):fcab222. PubMed ID: 34632383
[TBL] [Abstract][Full Text] [Related]
15. A Single-Arm Open-Label Clinical Trial on the Efficacy and Safety of Sirolimus for Epileptic Seizures Associated with Focal Cortical Dysplasia Type II: A Study Protocol.
Kada A; Tohyama J; Shiraishi H; Takahashi Y; Nakagawa E; Akiyama T; Saito AM; Inoue Y; Kato M
Kurume Med J; 2021 Jul; 66(2):115-120. PubMed ID: 34135202
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
17. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia.
Leitner DF; Kanshin E; Askenazi M; Siu Y; Friedman D; Devore S; Jones D; Ueberheide B; Wisniewski T; Devinsky O
PLoS One; 2022; 17(5):e0268597. PubMed ID: 35587487
[TBL] [Abstract][Full Text] [Related]
18. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives.
Mühlebner A; Bongaarts A; Sarnat HB; Scholl T; Aronica E
J Anat; 2019 Sep; 235(3):521-542. PubMed ID: 30901081
[TBL] [Abstract][Full Text] [Related]
19. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
Citraro R; Leo A; Constanti A; Russo E; De Sarro G
Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
[TBL] [Abstract][Full Text] [Related]
20. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
